CLINICAL TRIALS

SPRING 2023

FOX CHASE CANCER CENTER DEPARTMENT OF HEMATOLOGY/ONCOLOGY & FOX CHASE-TEMPLE UNIVERSITY HOSPITAL DEPARTMENT OF BONE MARROW TRANSPLANT AND CELLULAR THERAPIES

ACUTE MYELOID LEUKEMIA

22-1030: Peter Abdelmessieh, DO — **NEWLY DIAGNOSED**

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

Drugs: Venetoclax and Azacitidine + Magrolimab/Placebo

Key Eligibility

- Inclusion: Previously untreated AML who are ineligible for treatment w/ a standard cytarabine and anthracycline induction regimen due to age, comorbidity, or other factors

More Information: Allandria.Straker-Edwards@fccc.edu or 215-214-3022

LYMPHOMA

20-1066: Rashmi Khanal, MD — **FOR RELAPSED/REFRACTORY**

Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin Key Eligibility

Drugs: AB-101 (comprised of ex vivo-expanded allogeneic cord blood-derived natural killer (NK) cells cryopreserved in an infusion-ready suspension medium) w/ or w/o Rituximab

Key Eligibility:

- Inclusions:
  - Patients must have progressed beyond, have demonstrated intolerance to, or have declined treatment with available FDA-approved therapies for NHL
  - Permitted, but not required, prior lines:
    - Prior hematopoietic stem cell transplantation
    - Prior treatment(s) with an FDA-approved CAR-T
    - Prior treatment(s) with an investigational
- Exclusions:
  - Excluded sub-types: AIDS-associated lymphoma, Burkitt's lymphoma, CNS lymphoma, Post-transplant lymphoproliferative disorder, Castleman's Disease, and High-grade B-cell lymphomas not otherwise specified
  - No active CNS lymphoma, or involvement of the CNS unless there is a history of at least 3 months of sustained remission among those with treated disease

More Information: Nicole.Ahrens@fccc.edu or 215-214-3173

22-1021: Rashmi Khanal, MD — **LYMPHOMA UNDERGOING HD-AHCT**

A Phase 3 Double-Blind, Randomized, Placebo controlled Study to Evaluate the Efficacy and Safety of AB-205 plus Standard of Care versus Placebo plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)

Drugs: AB-205/placebo + SoC

Key Eligibility:

- Inclusion:
  - Diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma
  - Candidates for HDT-AHCT with one of the following condition regimens: BEAM or BeEAM
  - achieved CR or PR prior to planned HDT
- Exclusion:
  - CNS lymphoma
  - prior HCT

More Information: Allandria.Straker-Edwards@fccc.edu or 215-214-3022

FOX CHASE CANCER CENTER
TEMPLE HEALTH

FOX CHASE-TEMPLE UNIVERSITY HOSPITAL
BONE MARROW TRANSPLANT PROGRAM
All hospital services provided by Temple University Hospital

CLINICAL TRIALS

LYMPHOMA

22-1026: Marcus Messmer, MD **FOR RELAPSED/REFRACTORY AND NEWLY DIAGNOSED**

Protocol # 22-1026: A Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

Drugs: Epcoritamab + chemotherapy

Key Eligibility:

- Inclusion:
  - DLBCL with histologically confirmed CD20+ disease- included DLBCL (NOS), High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations, FL Grade 3B
  - no prior treatment with Epcoritamab or any other bispecific antibody targeting CD3 and CD20 DLBCL

More Information: Jill.Samaha@fccc.edu or 215-214-3125

22-1046: Shazia Nakhoda, MD

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤ 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-cell Lymphoma

Drugs: Acalabrutinib

Key Eligibility:

- Inclusion:
  - No prior treatment for DLBCL, except prior steroids and/or vincristine prophase as well as CNS prophylaxis
  - IPI score of 1-5. Subjects with IPI 1 must be Ann Arbor Stage III or IV-FDG-avid measurable disease
- Exclusion:
  - Known CNS lymphoma
  - Prior history of indolent lymphoma or CLL
  - Known high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)

More Information: Nicole.Ahrens@fccc.edu or 215-214-3173

KEY ACCOUNT MANAGEMENT TEAM

If you have any questions, our key account management team is here to help you.

Sharon Klaver
sharon.klaver@fccc.edu
267-990-1254

Laura Higdon
laura.higdon@fccc.edu
267-605-2020

Joseph Karensky
joseph.karensky@fccc.edu
445-206-5228

Diane Brown
diane.brown@fccc.edu
215-880-9969

CONTACT US

For general questions about clinical trials, call **215-214-1515** or visit **FoxChase.org/clinicaltrials**.

To refer a patient to a clinical trial listed here, see the "More Information" section within each listing.

New clinical trials are continuously being added. For updated information, visit **FoxChase.org/hemetrials**.

FOX CHASE CANCER CENTER
TEMPLE HEALTH

FOX CHASE-TEMPLE UNIVERSITY HOSPITAL
BONE MARROW TRANSPLANT PROGRAM
All hospital services provided by Temple University Hospital